Thymoquinone and Poloxin are slow-irreversible inhibitors to human Polo-like kinase 1 Polo-box domain

Journal of Medical Colleges of PLA

Volumn 25, Issue 3, 2010, Pages 136-142

  Zhou, Yin ^a   Jianhua, Chen ^a   Rehse, Peter H ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Shanghai Medicilon Inc   (China)

Author keywords

Fluorescence polarization; Irreversible inhibitor; Kinetics; Polo like kinase

Indexed keywords

ENZYME INHIBITOR; POLO LIKE KINASE 1; POLOXIN; THYMOQUINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE POLARIZATION; ISOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 77955040022     PISSN: 10001948     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1000-1948(10)60032-9     Document Type: Article

References (24)

1. Mundt KE, Golsteyn RM, Lane HA, et al. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 1997, 239(2):377-385.
2. Nigg EA Polo-like kinases: positive regulators of cell division from start to finish. Cur Opin Cell Biol 1998, 10(6):776-783.
3. García-Alvarez B, de Cárcer G, Ibañez S, et al. Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc Natl Acad Sci USA 2007, 104(9):3107-3112.
4. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007, 17(4):316-322.
5. Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009, 15(9):3094-3102.
6. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005, 7(3):275-286.
7. Strebhardt K, Ullrich A Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6(4):321-330.
8. Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009, 16(8):876-882.
9. Elia AE, Cantley LC, Yaffe MB Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003, 299(5610):1228-1231.
10. Reindl W, Yuan J, Krämer A, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008, 15(5):459-466.
11. Lee KS, Idle JR Pinning down the polo-box domain. Chem Biol 2008, 15(5):415-416.
12. Reindl W, Strebhardt K, Berg T A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 2008, 383(2):205-209.
13. Gooljarsingh LT, Fernandes C, Yan K, et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA 2006, 103(20):7625-7630.
14. Braz VA, Holladay LA, Barkley MD Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. Biochemistry 2010, 49(3):601-610.
15. Dash C, Phadtare S, Deshpande V, et al. Structural and mechanistic insight into the inhibition of aspartic proteases by a slow-tight binding inhibitor from an extremophilic Bacillus sp.: correlation of the kinetic parameters with the inhibitor induced conformational changes. Biochemistry 2001, 40(38):11525-11532.
16. Liang Y, Patel SS, Dean DH Irreversible binding kinetics of Bacillus thuringiensis CryIA delta-endotoxins to gypsy moth brush border membrane vesicles is directly correlated to toxicity. J Biol Chem 1995, 270(42):24719-24724.
17. Wilkes SH, Prescott JM The slow, tight binding of bestatin and amastatin to aminopeptidases. J Biol Chem 1985, 260(24):13154-13162.
18. Groebe DR, Abramson SN Lophotoxin is a slow binding irreversible inhibitor of nicotinic acetylcholine receptors. J Biol Chem 1995, 270(1):281-286.
19. Dinos GP, Connell SR, Nierhaus KH, et al. Erythromycin, roxithromycin, and clarithromycin: use of slow-binding kinetics to compare their in vitro interaction with a bacterial ribosomal complex active in peptide bond formation. Mol Pharmacol 2003, 63(3):617-623.
20. Reindl W, Yuan J, Krämer A, et al. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem 2009, 10(7):1145-1148.
21. Watanabe N, Sekine T, Takagi M, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009, 284(4):2344-2353.
22. Li L, Wang X, Chen J, et al. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmacol Sin 2009, 30(10):1443-1453.
23. Brune K, Neubert A Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol 2001, 19(6 Suppl 25):S51-S57.
24. Luckner SR, Liu N, Am Ende CW, et al. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem 2010, 285(19):14330-14337.